Taiwan Liposome Seeks To Teach Old Drugs New Tricks In China And Markets Far From Home
This article was originally published in PharmAsia News
Taiwan Liposome Co. Ltd. has the funds and team to reach outside of its base in Taiwan to turn old drugs into new products and is looking for opportunities at Asia-specific product applications.
You may also be interested in...
Sandoz will commercialize TLC’s liposomal amphotericin B product, a generic of Gilead’s AmBisome, in the U.S. and EU.
Generon in Shanghai was founded by former Hutchison MediPharma employees to target a niche market between expensive import drugs and lower quality domestic products.
CEO Jason Kang, former chief scientist at Beta Pharma, is building a pipeline of Class I molecules with experience on what it takes to build a start-up company in China.